Going-concern and financing risk
The company has disclosed substantial doubt about its ability to continue as a going concern, making access to capital critical.
- Scope
- Equity financing and operating runway
- Materiality
- high
PetVivo Holdings, Inc. is a U.S.-based animal health company focused on veterinary medical devices and therapeutics. Its core commercial product is Spryng®, which is sold to veterinarians and distributed through animal-health wholesalers and distribution partners.
−749,1 %
66,1 %
−917,4 %
+0,8 %
1.35
0.96
| % | |
|---|---|
| Spryng® product sales | 100% Sales of the company's lead veterinary medical device used in animal care settings. |
| Direct veterinary sales | 0% Sales made directly to veterinarians through the company's own sales efforts. |
| Distributor sales | 0% Sales routed through animal-health distribution partners such as MWI, Covetrus, Vedco, and Clipper. |
PetVivo sells primarily into the veterinary market, where veterinarians buy Spryng® for use in animal treatment...
Buy Spryng® directly for use in treating animal patients and for clinic inventory.
Purchase and resell Spryng® to veterinary customers through established distribution networks.
Use or stock the product as part of routine animal care and treatment workflows.
Influence demand indirectly through willingness to pursue veterinarian-recommended treatments.
PetVivo is headquartered in the United States and its commercial activity is centered on the U.S. veterinary market...
PetVivo’s strategy is to expand commercialization of Spryng® through a mix of direct sales and third-party distribution...
Revenue growth depends on broader veterinarian adoption and stronger channel execution.
Third-party distributors extend market reach and are important to product placement.
Awareness and promotion are necessary to drive veterinarian demand in a competitive market.
PetVivo faces execution risk because its business depends on building a sales force, managing distributors, and...
The company has disclosed substantial doubt about its ability to continue as a going concern, making access to capital critical.
The company’s revenue base is concentrated in a single lead product, so weak adoption would directly limit growth.
A large share of revenue is generated through distributors, so partner changes can quickly affect sales reach.
Loss of a senior exchange listing can reduce liquidity, investor access, and financing flexibility.
Competitors have greater financial, technical, and commercial resources and established brands.
WOOF · Retail-Retail Stores, NEC
NVNO · Surgical & Medical Instruments & Apparatus
enVVeno Medical Corp is a U.S.-based medical device company focused on developing bioprosthetic venous valve technologies for severe chronic venous insufficiency.
PAHC · Pharmaceutical Preparations
PBSV · Services-Management Consulting Services
ELAN · Pharmaceutical Preparations
Elanco Animal Health is a U.S.-based animal health company that develops and sells medicines, vaccines, feed additives and related services for pets and farm animals.
INO · Pharmaceutical Preparations
INOVIO Pharmaceuticals is a clinical-stage biotechnology company developing DNA medicines designed to help treat and protect people from HPV-associated diseases, cancer, and infectious diseases.
: 29/04/2026